Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States

World Journal of Gastroenterology

Volumn 15, Issue 35, 2009, Pages 4415-4422

  Saif, Muhammad Wasif ^a   Shi, Nianwen ^b   Zelt, Susan ^c  

^a Yale Medical Oncology   (United States)

^b THOMSON REUTERS   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 fluorouracil; Capecitabine; Gastroesophageal cancer; Hand foot syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; ARTICLE; BONE MARROW DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG USE; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL SURGERY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; SKIN DISEASE; STOMACH CANCER; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 72049114444     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4415     Document Type: Article

References (11)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150 (Pubitemid 46655601)
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Esophageal cancer. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; 2007. Available from: URL: http://www.nccn.org
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Gastric cancer. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; 2007. Available from: URL: http://www.nccn.org
4. American Cancer Society. Cancer facts and figures 2006. Atlanta, GA: American Cancer Society; 2006. Publication 500806. Available from: URL: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. Accessed September 5, 2008
5. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289
6. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002; 37: 1359-1365 (Pubitemid 36051495)
7. Corporaal S, Smit WM, Russel MG, van der Palen J, Boot H, Legdeur MC. Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. Neth J Med 2006; 64: 141-146 (Pubitemid 43772037)
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 (Pubitemid 34936653)
9. Casaretto L, Sousa PL, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res 2006; 39: 431-440
10. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
11. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673